There lies a problem I've mentioned before. Pancreatic cancer spreads very quickly. Find patients that meet the criteria will be slim to none. Pmcb cannot compete head to head so they opted to take the leftovers so to speak. Unfortunately those patients will be in to bad of shape to fit the criteria.
Quote: "Only patients who have locally advanced, non-metastatic, inoperable cancers and whose tumors no longer respond after 4-6 months of treatment with either the nab-paclitaxel (Abraxane®) + gemcitabine or FOLFIRINOX regimens will be eligible for the study. "
News 
Market Data 
Discover 
